Ono Pharmaceutical Co Ltd banner

Ono Pharmaceutical Co Ltd
OTC:OPHLF

Watchlist Manager
Ono Pharmaceutical Co Ltd Logo
Ono Pharmaceutical Co Ltd
OTC:OPHLF
Watchlist
Price: 14.55 USD 3.93% Market Closed
Market Cap: $6.9B

Wall St Price Targets

OPHLF Price Targets Summary
Ono Pharmaceutical Co Ltd

Wall Street analysts forecast OPHLF stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OPHLF is 15.1 USD with a low forecast of 11.62 USD and a high forecast of 19.79 USD.

Lowest Forecast
Price Target
11.62 USD
20% Downside
Average Forecast
Price Target
15.1 USD
4% Upside
Highest Forecast
Price Target
19.79 USD
36% Upside
Ono Pharmaceutical Co Ltd Competitors:
Price Targets
PALI
Palisade Bio Inc
480% Upside

Revenue
Forecast

9% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 2 years is -6%.

Gross Profit
Forecast

9% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
-4% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 2 years is -4%.

Operating Income
Forecast

7% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss
7% / Year
Past Growth
30% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 1 year is 30%.

Pre-Tax Income
Forecast

6% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
6% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 2 years is -6%.

Net Income
Forecast

8% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
8% / Year
Past Growth
-6% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 2 years is -6%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is OPHLF's stock price target?
Price Target
15.1 USD

According to Wall Street analysts, the average 1-year price target for OPHLF is 15.1 USD with a low forecast of 11.62 USD and a high forecast of 19.79 USD.

What is the Revenue forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-6%

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 2 years is -6%.

What is the Gross Profit forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-4%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 2 years is -4%.

What is the Operating Income forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
30%

Over the last 14 years, the compound annual growth rate for Operating Income has been 7%. The projected CAGR for the next 1 year is 30%.

What is the Pre-Tax Income forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-6%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 6%. The projected CAGR for the next 2 years is -6%.

What is the Net Income forecast for Ono Pharmaceutical Co Ltd?
Projected CAGR
-6%

Over the last 14 years, the compound annual growth rate for Net Income has been 8%. The projected CAGR for the next 2 years is -6%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett